Shares of Geron Corporation (NASDAQ:GERN) have received an average rating of “Hold” from the seven ratings firms that are currently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, four have given a hold recommendation and two have given a buy recommendation to the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $3.75.
Several research firms have recently commented on GERN. BidaskClub lowered Geron Corporation from a “hold” rating to a “sell” rating in a report on Saturday, August 5th. Zacks Investment Research lowered Geron Corporation from a “buy” rating to a “hold” rating in a report on Wednesday, June 14th. Finally, FBR & Co reissued a “buy” rating on shares of Geron Corporation in a report on Tuesday, July 4th.
Geron Corporation (NASDAQ GERN) opened at 2.12 on Wednesday. The stock’s market capitalization is $337.53 million. The firm has a 50 day moving average price of $2.23 and a 200 day moving average price of $2.47. Geron Corporation has a 52 week low of $1.81 and a 52 week high of $3.15.
Geron Corporation (NASDAQ:GERN) last posted its earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($0.04) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.05) by $0.01. The company had revenue of $0.17 million during the quarter, compared to analyst estimates of $0.38 million. Geron Corporation had a negative return on equity of 21.30% and a negative net margin of 433.72%. The business’s revenue was down 19.0% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.05) earnings per share. Equities research analysts predict that Geron Corporation will post ($0.18) earnings per share for the current year.
COPYRIGHT VIOLATION NOTICE: “Geron Corporation (GERN) Given Consensus Rating of “Hold” by Analysts” was first reported by Stock Observer and is owned by of Stock Observer. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of United States & international trademark and copyright legislation. The correct version of this piece of content can be read at https://www.thestockobserver.com/2017/09/13/geron-corporation-gern-given-consensus-rating-of-hold-by-analysts.html.
A number of hedge funds have recently modified their holdings of the stock. Raymond James Financial Services Advisors Inc. grew its holdings in Geron Corporation by 1.8% in the 2nd quarter. Raymond James Financial Services Advisors Inc. now owns 58,056 shares of the biopharmaceutical company’s stock worth $161,000 after buying an additional 1,000 shares in the last quarter. Creative Planning grew its holdings in Geron Corporation by 1.3% in the 2nd quarter. Creative Planning now owns 103,213 shares of the biopharmaceutical company’s stock worth $286,000 after buying an additional 1,345 shares in the last quarter. IHT Wealth Management LLC bought a new position in Geron Corporation in the 2nd quarter worth approximately $122,000. Tudor Investment Corp ET AL grew its holdings in Geron Corporation by 12.1% in the 1st quarter. Tudor Investment Corp ET AL now owns 52,369 shares of the biopharmaceutical company’s stock worth $119,000 after buying an additional 5,669 shares in the last quarter. Finally, American International Group Inc. grew its holdings in Geron Corporation by 7.1% in the 1st quarter. American International Group Inc. now owns 92,964 shares of the biopharmaceutical company’s stock worth $211,000 after buying an additional 6,140 shares in the last quarter. 38.79% of the stock is owned by institutional investors and hedge funds.
Geron Corporation Company Profile
Geron Corporation (Geron) is a biopharmaceutical company, which supports the clinical stage development of a telomerase inhibitor, Imetelstat, in hematologic myeloid malignancies by Janssen Biotech, Inc (Janssen). The Company is engaged in the development of therapeutic products for oncology. Using its nucleic acid chemistry, Geron designed Imetelstat to be an oligonucleotide that binds with high affinity to the ribonucleic acid (RNA) template of telomerase, thereby directly inhibiting telomerase activity.
Receive News & Ratings for Geron Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Geron Corporation and related companies with MarketBeat.com's FREE daily email newsletter.